# Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT

> **NCT05614518** · PHASE3 · COMPLETED · sponsor: **HTA Co., Ltd.** · enrollment: 280 (actual)

## Conditions studied

- Bone Metastases

## Interventions

- **DRUG:** Sodium Fluoride F-18 Injection
- **DRUG:** Technetium[99mTc] Methylenediphosphonate Injection

## Key facts

- **NCT ID:** NCT05614518
- **Lead sponsor:** HTA Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2022-06-02
- **Final completion:** 2022-06-02
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05614518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05614518, "Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05614518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*